Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.23.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.104 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.104 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.198NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.198NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
EG.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.5.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BN.1.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.66NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.66NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.485NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.485NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CP.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CP.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.73NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.73NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.112.2 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.112.2 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.21NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.36.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.134NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.134NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.39.1.3 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
AY.39.1.3 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.4NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BN.1.3.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.38NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
C.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
C.26NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
C.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Q.4 (Alpha)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Q.4 (Alpha)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.442NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.442NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.1 (Gamma)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.1.1 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.2.5.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
A.2.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CR.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CR.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
DV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BT.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BT.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BE.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FS.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used